Abstract
Obesity has reached epidemic proportions worldwide and is now a major healthcare problem. Likewise, there are a number of cardiovascular risk factors and metabolic factors associated with obesity and this clustering contributes to the disease known as metabolic syndrome or syndrome X. Metabolic syndrome over a number of years can cause end organ damage resulting in morbidity and mortality. Metabolic syndrome and obesity are major contributing factors to the increase in nephropathy and end stage renal disease. Interestingly, an imbalance between cyclooxygenase-2 (COX-2) and cytochrome P450 (CYP450) enzymes in the kidney may contribute to the nephropathy associated with metabolic syndrome. Recent studies have demonstrated that COX-2 inhibition decreases renal cytokine levels and glomerular injury in obese rats. Therefore, COX-2 and CYP450 metabolites are therapeutic targets for the treatment of renal disease related to metabolic syndrome.
Keywords: Epoxyeicosatrienoic acids, endothelium-derived hyperpolarizing factor, kidney, obesity, CYP450 metabolites
Current Enzyme Inhibition
Title: Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease
Volume: 2 Issue: 1
Author(s): John D. Imig and Xueying Zhao
Affiliation:
Keywords: Epoxyeicosatrienoic acids, endothelium-derived hyperpolarizing factor, kidney, obesity, CYP450 metabolites
Abstract: Obesity has reached epidemic proportions worldwide and is now a major healthcare problem. Likewise, there are a number of cardiovascular risk factors and metabolic factors associated with obesity and this clustering contributes to the disease known as metabolic syndrome or syndrome X. Metabolic syndrome over a number of years can cause end organ damage resulting in morbidity and mortality. Metabolic syndrome and obesity are major contributing factors to the increase in nephropathy and end stage renal disease. Interestingly, an imbalance between cyclooxygenase-2 (COX-2) and cytochrome P450 (CYP450) enzymes in the kidney may contribute to the nephropathy associated with metabolic syndrome. Recent studies have demonstrated that COX-2 inhibition decreases renal cytokine levels and glomerular injury in obese rats. Therefore, COX-2 and CYP450 metabolites are therapeutic targets for the treatment of renal disease related to metabolic syndrome.
Export Options
About this article
Cite this article as:
Imig D. John and Zhao Xueying, Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease, Current Enzyme Inhibition 2006; 2 (1) . https://dx.doi.org/10.2174/157340806775473544
DOI https://dx.doi.org/10.2174/157340806775473544 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents on Accuracy of Blood Pressure Measurement
Recent Patents on Biomedical Engineering (Discontinued) Preventive and Therapeutic Role of Muscle Contraction Against Chronic Diseases
Current Pharmaceutical Design Epidemiology of Diabetes Mellitus in the United Arab Emirates
Current Diabetes Reviews Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Fibrates and Statins in the Treatment of Diabetic Retinopathy
Current Pharmaceutical Biotechnology Abietane Diterpenes as Potential Candidates for the Management of Type 2 Diabetes
Current Pharmaceutical Design Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Editorial on the Occasion of the 20th Anniversary of Endocrine Metabolic Immune Disorders-Drug Targets Journal with a Kaleidoscopic Vision of Selected Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets Renin-Angiotensin System in Diabetes
Protein & Peptide Letters Glomerular Endothelium and its Impact on Glomerular Filtration Barrier in Diabetes: Are the Gaps Still Illusive?
Current Medicinal Chemistry Epidemiology and Costs of Hypertension-related Disorders
Current Pharmaceutical Design The Roles of Abnormal Renal Sodium Handling in Hypertension Associated with Metabolic Syndrome
Current Hypertension Reviews Role of Chymase in Preeclampsia
Current Vascular Pharmacology Subject Index To Volume 3
Vascular Disease Prevention (Discontinued) Uric acid and Metabolic Syndrome: What is the Relationship?
Current Rheumatology Reviews Psoriasis and Vascular Risk : An Update
Current Pharmaceutical Design Lessons from the REACH Registry in Europe
Current Vascular Pharmacology The Importance of Novel Inflammatory Biomarkers in Renal Disease
Current Medicinal Chemistry Immunoglobulin Free Light Chains in Immune Responses
Current Immunology Reviews (Discontinued) Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets